// App-Quantinova.ai

BSH19‐PO‐113 : Boterzomib‐thalidomide‐dexamethasone induction therapy in myeloma is superior to bortezomib‐cyclophosphamide‐dexamethasone with lower rates of neuropathy: real world data

Researchers

Presenter

  • F. Al-Kaisi

Principal Investigators

  • C. Williams

  • F. Wadelin

  • E. Das-Gupta

  • S. Henshaw

  • S. Adams

  • D. Smith

Medical Centers

  • Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Peripheral Nervous System

  • Oncology (ONC)

Disease

  • Peripheral neuropathy

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Thalidomide

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved